South Korean aesthetics company Jeisys Medical (Jeisys Medical) is advancing toward becoming a global comprehensive aesthetics player after its botulinum toxin JTM201 succeeded in China Phase 3 trials. With filler revenue crossing KRW 100 billion and a proactive asset sale to improve its balance sheet, the company is drawing renewed attention from overseas buyers and distributors watching for new injectable supply opportunities.
China Phase 3 Results Confirm Efficacy and Safety
Jeisys Medical announced on May 29 that it received the Clinical Study Report (CSR) approval for JTM201 from Chinese authorities, confirming the toxin’s efficacy and safety in a Phase 3 trial involving 506 adult patients with moderate-to-severe glabellar lines. The study demonstrated non-inferiority versus the control group, with an investigator-assessed improvement rate of 77.8% at four weeks post-injection. Over 60% of patients still perceived effect at 16 weeks, indicating durable longevity.
Path to China BLA and Revenue Timeline
A company official stated, “Based on this Phase 3 CSR, we plan to submit a Biologics License Application (BLA) in China within the first half of this year.” The company expects JTM201 to begin generating meaningful revenue in China from next year, adding to existing HA filler sales. This timeline is critical for importers and distributors eyeing the world’s second-largest aesthetics market.
Filler Business Expands into New Markets
Jeisys Medical’s HA filler brand e.p.t.q. is already exported to over 80 countries. This year, the company plans to start generating new revenue from China and the United States. It is also expanding its filler lineup beyond facial products to include chin and body fillers (e.g., S700), aiming to increase market share. Additionally, the company recently obtained halal certification from Indonesia’s BPJPH, strengthening its entry into Southeast Asian and Middle Eastern markets.
Financial Risk Mitigation Through Asset Sale
Jeisys Medical is executing a sale-and-leaseback of its Pangyo Global R&D Center, expected to close within Q2. The transaction will raise approximately KRW 33 billion (USD 25 million) in cash. The funds will be used to address the overhang from convertible bonds maturing in July and to repay real estate-backed loans, reducing debt ratio and financial costs. Analyst Kim Da-hye of Hana Securities noted, “The overhang risk that worried investors most will be resolved with the CB maturity on July 6. After that, derivative valuation losses will disappear, enabling a turnaround in net profit.”
What Buyers Should Watch
For overseas importers and distributors, Jeisys Medical’s dual filler-toxin portfolio now offers a more complete sourcing option. The China BLA submission timeline and the company’s expanding filler range (including body and halal-certified products) signal new supply-chain opportunities. The improved financial health also reduces counterparty risk for long-term procurement contracts.
Source: Read the original report | Published: June 04, 2026